Alectinib D8

Alectinib D8 is a deuterated form of Alectinib, a drug used in the treatment of non-small cell lung cancer (NSCLC). Alectinib D8 has the same chemical formula as Alectinib, but it contains eight deuterium atoms instead of hydrogen atoms. This makes it a useful tool for studying the pharmacokinetics and metabolism of Alectinib, as well as for improving the accuracy of pharmacokinetic studies. Alectinib D8 works by inhibiting the activity of anaplastic lymphoma kinase (ALK), which is a protein that is overactive in some types of cancer cells. By blocking the activity of ALK, Alectinib D8 helps to slow or stop the growth of cancer cells in the body. The chemical structure of Alectinib D8 consists of a pyridine ring, a pyrimidine ring, and a benzene ring. It has a molecular weight of 534.7 g/mol and a melting point of approximately 170-175°C. Alectinib D8 is administered orally in capsule form, and the recommended dosage varies depending on the individual patient's needs. It is metabolized in the liver and excreted primarily in the feces. Like all drugs, Alectinib D8 can cause side effects, including nausea, vomiting, diarrhea, fatigue, and muscle weakness. Patients taking Alectinib D8 should be closely monitored for any signs of adverse effects and should follow their doctor's instructions carefully.